Ernexa Therapeutics Inc

Ernexa Therapeutics’ Q1 2026 filing reveals key financials, upcoming July 1 shareholder meeting, and its mRNA‑based biotech strategy.

Ernexa Therapeutics Inc. has announced a 1-for-15 reverse stock split to regain compliance with Nasdaq’s listing requirements, but the move raises concerns about the company’s financial health and market performance.